Mulham Ombada, MD (@mombada1) 's Twitter Profile
Mulham Ombada, MD

@mombada1

🇸🇩 🇺🇸 | HPM Fellow @RoswellPark | IM Residency @Upstatenews | Interests: #MedEd #PallOnc #MalignantHem | Aspiring Oncologist | Views my own

ID: 1683292063306006529

calendar_today24-07-2023 01:44:45

161 Tweet

153 Followers

410 Following

Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

⭐️Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers AACR Cancer Discovery Elizabeth McKenna #LiquidBiopsy #PrecisionMedicine aacrjournals.org/cancerdiscover…

Nazli Dizman (@nazlidizman) 's Twitter Profile Photo

🎉Immensely excited and proud to share with you our recent paper "Guide to Understanding and Supporting #InternationalMedicalGraduates in #Hematology #Oncology" with gratitude to my co-first author Ziad Bakouny, MD, MSc, senior authors Toni Choueiri, MD #DrAlfredLee, and other world-renowned

🎉Immensely excited and proud to share with you our recent paper "Guide to Understanding and Supporting #InternationalMedicalGraduates in #Hematology #Oncology" with gratitude to my co-first author <a href="/ZiadBakouny/">Ziad Bakouny, MD, MSc</a>, senior authors <a href="/DrChoueiri/">Toni Choueiri, MD</a> #DrAlfredLee, and other world-renowned
Mulham Ombada, MD (@mombada1) 's Twitter Profile Photo

Thank you Karyopharm Therapeutics for the invite! Looking forward attending Dr. Niesvizky Ruben Niesvizky presentation on Friday, October 18th!  #MedTwitter #LLM #Myeloma

Thank you Karyopharm Therapeutics for the invite! 

Looking forward attending Dr. Niesvizky <a href="/RubenNiesvizky/">Ruben Niesvizky</a> presentation on Friday, October 18th! 

#MedTwitter #LLM #Myeloma
Dr Joseph McCollom DO (@realbowtiedoc) 's Twitter Profile Photo

Charles von Gunten is a true #pallonc legend and foundational for #hpm #hapc training. Grateful to have caught him at #hapc23 Join our ASCO PallOnc Community of Practice crew on Oct 24th 4p EST for a fireside chat with many of program directors of these innovative #supponc fellowships too!

<a href="/CvonGunten/">Charles von Gunten</a> is a true #pallonc legend and foundational for #hpm #hapc training. Grateful to have caught him at #hapc23 

Join our <a href="/PallOncCoP/">ASCO PallOnc Community of Practice</a> crew on Oct 24th 4p EST for a fireside chat with many of program directors of these innovative #supponc fellowships too!
Dr Joseph McCollom DO (@realbowtiedoc) 's Twitter Profile Photo

The #pallonc study that rocked #ESMO24 in NEJM Ph 2 trial of ponsegromab antiGDF-15 in 185 pts: ⬆️weight gain ⚖️ ⬆️appetite 😋 ⬆️physical activity 🏃 ⬇️ #cachexia #supponc ASCO PallOnc Community of Practice OncoAlert🚨 @MDRoeland Richard Dunne, MD 🔗: nejm.org/doi/full/10.10…

The #pallonc study that rocked #ESMO24 in <a href="/NEJM/">NEJM</a> 

Ph 2 trial of ponsegromab antiGDF-15 in 185 pts: 
⬆️weight gain ⚖️
⬆️appetite 😋
⬆️physical activity 🏃
⬇️ #cachexia 

#supponc <a href="/PallOncCoP/">ASCO PallOnc Community of Practice</a> <a href="/OncoAlert/">OncoAlert</a>🚨 @MDRoeland <a href="/DrR_DUNNE/">Richard Dunne, MD</a> 
🔗: nejm.org/doi/full/10.10…
Viren Kaul, MD (@virenkaul) 's Twitter Profile Photo

Visual on why 14G = large bore Not 16G, not 18G Ask your team deliberately: “What size IV access do we have?” As opposed to, “Do we have access?” H/T Oren Gottfried, MD

Mulham Ombada, MD (@mombada1) 's Twitter Profile Photo

Excited to share that our new abstract “Struck by Tsunami: Difficult Case of a Severe Refractory ITP” got approved for publication at @BloodJournal. Grateful for the tremendous support by my mentor Dr. Teresa Gentile and all collaborators. #MedTwitter #ITP #SuppOnc

Excited to share that our new abstract “Struck by Tsunami: Difficult Case of a Severe Refractory ITP” got approved for publication at @BloodJournal.

Grateful for the tremendous support by my mentor Dr. Teresa Gentile and all collaborators.

#MedTwitter #ITP #SuppOnc
ASCO PallOnc Community of Practice (@pallonccop) 's Twitter Profile Photo

Grateful to everyone who works in the palliative care space- ensuring patients receive holistic and goal concordant care at all stages of the care continuum.

OncoDaily (@oncodaily) 's Twitter Profile Photo

Difficult Case of a Severe Refractory ITP - Mulham Ombada, MD @BloodJournal oncodaily.com/blog/163371 #BloodJournal #Cancer #OncoDaily #Oncology #Medicine #Health #MedEd #MedX #MedNews

Mulham Ombada, MD (@mombada1) 's Twitter Profile Photo

My first E-Poster presentation ✅  Attended amazing learning sessions ✅  Grateful for the collaboration opportunity with my respectful mentors & colleagues 🙏   Thank you Lymphoma, Leukemia & Myeloma Congress for this great meeting experience✌️  #MedTwitter #LLMCongress2024

My first E-Poster presentation ✅ 
Attended amazing learning sessions ✅ 

Grateful for the collaboration opportunity with my respectful mentors &amp; colleagues 🙏  

Thank you <a href="/llmcongress/">Lymphoma, Leukemia & Myeloma Congress</a> for this great meeting experience✌️ 

#MedTwitter #LLMCongress2024
OncoDaily (@oncodaily) 's Twitter Profile Photo

My first E-Poster presentation at LLM Congress 2024 - Mulham Ombada, MD Lymphoma, Leukemia & Myeloma Congress oncodaily.com/url/170540 #LLMCongress2024 #HemOnc #Cancer #MedEd #MedNews #Health #Medicine #MedTwitter #OncoDaily #Oncology

My first E-Poster presentation at LLM Congress 2024 - <a href="/MOmbada1/">Mulham Ombada, MD</a> 
<a href="/llmcongress/">Lymphoma, Leukemia & Myeloma Congress</a> 

oncodaily.com/url/170540

#LLMCongress2024 #HemOnc #Cancer #MedEd #MedNews #Health #Medicine #MedTwitter #OncoDaily #Oncology
Robert Z. Orlowski (@myeloma_doc) 's Twitter Profile Photo

#Myeloma Paper of the Day: Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory myeloma achieve higher response rates (100% in 52 pts) vs. other options & increase clonality in the CD4+ and CD8+ T cell post_CAR T: pubmed.ncbi.nlm.nih.gov/39441177/. #mmsm

#Myeloma Paper of the Day: Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory myeloma achieve higher response rates (100% in 52 pts) vs. other options &amp; increase clonality in the CD4+ and CD8+ T cell post_CAR T: pubmed.ncbi.nlm.nih.gov/39441177/. #mmsm
Dr Joseph McCollom DO (@realbowtiedoc) 's Twitter Profile Photo

Nothing gives me a boost like meeting with my ASCO PallOnc Community of Practice family. Combine that with my love of #nerdy 🤓 and this is going to be a dynamite collaboration. Make sure you don't miss out next week. Join us! #hpm #hapc #pallonc #supponc #AI #healthIT Danijela Jakovljevic Richa Thakur, MD

Rahul Banerjee, MD, FACP (@rahulbanerjeemd) 's Twitter Profile Photo

Excellent Journal of Clinical Oncology editorial by Sagar Lonial MD Shaji Kumar about CARTITUDE-1, with 5-yr PFS of 33% off all treatment in myeloma! 👏 for CAR-T. Most thoughtful discussion of cure in #MMsm I’ve read… the MGUS-like MRD-positive phenotype 👇 needs to be part of the discussion!

Excellent <a href="/JCO_ASCO/">Journal of Clinical Oncology</a> editorial by <a href="/SagarLonialMD/">Sagar Lonial MD</a> <a href="/myelomaMD/">Shaji Kumar</a> about CARTITUDE-1, with 5-yr PFS of 33% off all treatment in myeloma! 👏 for CAR-T.

Most thoughtful discussion of cure in #MMsm I’ve read… the MGUS-like MRD-positive phenotype 👇 needs to be part of the discussion!
Fawzi Abu Rous, MD (@fawziaburous) 's Twitter Profile Photo

August 1 marks #WorldLungCancerDay — a time to reflect, raise awareness, and recommit to changing the future of lung cancer. We’ve made meaningful progress, but there’s still a long way to go. Each patient, each study, each step forward brings us closer to better outcomes.

August 1 marks #WorldLungCancerDay — a time to reflect, raise awareness, and recommit to changing the future of lung cancer.

We’ve made meaningful progress, but there’s still a long way to go. Each patient, each study, each step forward brings us closer to better outcomes.
Jordan Gauthier (@drjgauthier) 's Twitter Profile Photo

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet thelancet.com/journals/lance…